Dr. Phillip Kim is the CEO and founder of Trutino Biosciences, a San Diego-based biotech company dedicated to advancing cytokine-based biologics. These engineered biologics are designed to activate immune responses specifically within tumor environments, offering targeted cancer treatments with reduced systemic toxicity. Kim's extensive background in scientific research and biotech management, including previous leadership roles such as VP of R&D at Pierian Biosciences and Senior Director at Prometheus Laboratories (a Nestlé Health Science subsidiary), has informed his innovative direction at Trutino, particularly through their proprietary Zytokine™ platform. Under Kim’s leadership, Trutino has established strategic partnerships with major pharmaceutical companies, including a substantial option agreement with Boehringer Ingelheim. By aligning Trutino’s cytokine technology with the industry’s push for novel biologic therapies in oncology, Kim has successfully positioned Trutino as an attractive partner for enhancing oncology portfolios and exploring innovative treatment possibilities​.

As an advisor for AbVir Biotherapuetics, Dr. Kim brings valuable scientific and business expertise given his knowledge with biologics, enhanced corporate strategy insight, partnership development skills and track record in leadership and innovation.